Rhein lysinate induces apoptosis in breast cancer SK-Br-3 cells by inhibiting HER-2 signal pathway

Yaoxue Xuebao

Volumn 43, Issue 11, 2008, Pages 1099-1105

  Lin, Ya Jun ^a   Huang, Yun Hong ^a   Zhen, Yong Zhan ^a,b   Liu, Xiu Jun ^a   Zhen, Yong Su ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

^b NORTH CHINA COAL MEDICAL COLLEGE   (China)

Author keywords

Apoptosis; Breast neoplasm; HER 2 signal pathway; Rhein lysinate

Indexed keywords

ANTHRAQUINONE DERIVATIVE; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LYSINE; MESSENGER RNA; PROTEIN P53; RHEIN;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECT; FEMALE; GENETICS; HUMAN; IC 50; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTHRAQUINONES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; HUMANS; INHIBITORY CONCENTRATION 50; LYSINE; NF-KAPPA B; RECEPTOR, ERBB-2; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 56649101947     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. 2+ on rhein-induced apoptosis in human cervical cancer Ca Ski cells [J]. Anticancer Res, 2007,27:379-389.
2. 2+-dependent mitochondrial death pathway in human nasopharyngeal carcinoma cells [J]. Anticancer Res, 2007,27:3313-3322.
3. Whenham N, D'Hondt V, Piccart MJ. HER-2-positive breast cancer: from trastuzumab to innovatory anti-HER2 strategies [J]. Clin Breast Cancer, 2008,8:38-49.
4. Nishimura R, Okumura Y, Arima N. Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival [J]. Breast Cancer, 2008,15:57-64.
5. Doyle DM, Miller KD. Development of new targeted therapies for breast cancer [J]. Breast Cancer, 2008,15:49-56.
6. Bender LM, Nahta R. HER-2 cross talk and therapeutic resistance in breast cancer [J]. Front Biosci, 2008,13:3906-3912.
7. Xu H, Yu Y, Marciniak D, et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells [J]. Mol Cancer Ther, 2005,4:435-442.
8. Wang TX, Yang XH. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells [J]. Acta Pharm Sin, 2008,43:461-466.
9. Kong A, Calleja V, Leboucher P, et al. HER2 oncogenic function escapes EGFR tyrosine kinase inhibitors via activation of alternative HER receptors in breast cancer cells [J]. PLoS ONE, 2008,3:e2881.
10. Dieras V, Vincent-Salomon A, Degeorges A, et al. Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance [J]. Bull Cancer, 2007,94:259-266.
11. Cho HS, Mason K, Ramyar KX, et al. Structure of the extracellular region of HER-2 alone and in complex with the Herceptin Fab [J]. Nature, 2003,421:756-760.
12. Li J, Chen YN, Duan JC, et al. Effects of ErbB signal and protein kinase B on monkey cardiocyte apoptosis induced by rapid pacing [J]. Acta Pharm Sin, 2007,42:470-474.